ClinicalTrials.gg
RecruitingNCT07632820Updated Sep 9, 2026

Erector Spinae Plane Block Versus Trigger Point Injection for Chronic Thoracic Myofascial Pain

A Phase 4 interventional study of Erector Spinae Plane (ESP) Block with 0.5% Plain Bupivacaine and Trigger Point Injection (TPI) with 0.5% Plain Bupivacaine in Back Pain, sponsored by Mayo Clinic. Recruiting at 5 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Mayo Clinic · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 307 studies in Back Pain with a site in United States — 38 open to participants now, 51 under way, 4 of them phase 3. Back Pain · United States.

Planned enrollment
131st of 262
76 · median 76
Started
2026
with 9 others
Phase 4
30 of 307
4 open now
Primary completion
2029-08
later than 48 of 50 live
Registered
303rd of 307
by date
Lead sponsor
5 of 307
Mayo Clinic

Among the 307 studies in Back Pain with a site in United States, this one is the 131st largest by planned enrollment of the 262 interventional ones that give a count, is one of 10 that started in 2026, is one of 30 in phase 4, reaches primary completion later than 48 of the 50 other live ones, and was the 303rd registered.

Back Pain

729 studies on the registry are indexed under Back Pain; 110 are open to participants now.

Browse Back Pain studies →

Open to participants now

38 of the 307 studies in Back Pain with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Back Pain studies recruiting now, 29 (43%) set no upper age limit and 32 (47%) stop at 75 or younger; 3 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 307 studies in Back Pain with a site in United States, or all of them as a file.
02

Study summary

Chronic thoracic (mid-back) pain can be difficult to treat, and there is limited evidence to guide the use of injection therapies for pain arising from muscles and surrounding soft tissues. Two commonly used treatments are trigger point injections (TPI) and erector spinae plane (ESP) blocks, but no studies have directly compared their effectiveness for chronic thoracic myofascial pain. The purpose of this study is to compare pain relief, physical function, emotional well-being, patient satisfaction, and safety following treatment with either an ESP block or TPI. Participants will be randomly assigned to receive one of the two treatments. Researchers will follow participants for up to 12 weeks after the procedure and collect information through questionnaires and pain assessments.

03

Conditions studied

  • Back Pain

Browse trials for

Keywords

  • thoracic back pain
  • myofascial pain
  • thoracic myofascial pain
  • Trigger point injection
  • Erector spinae plane block
  • TPI
  • ESP block
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-80 years
  • Chronic thoracic myofascial pain lasting at least three months
  • Pain intensity of ≥4 on 11-point NRS
  • At least two of three following conditions: Focal thoracic paraspinal pain, palpable taut band, referred pain pattern with palpation

Exclusion criteria

Exclusion Criteria:

  • Thoracic radiculopathy
  • Cervical myelopathy with neurological deficit
  • Prior cervicothoracic spine surgery
  • Pregnancy or lactation
  • to local anesthetic
  • Active
  • Fibromyalgia
  • >40 kg/m2
  • Workers' compensation or active litigation related to thoracic pain
  • Acute herpes zoster or history of postherpetic neuralgia involving thoracic dermatomes
  • Current opioid use >50 morphine milligram equivalents daily
  • Severe psychiatric or cognitive disorders, specifically history of schizophrenia, chronic psychotic disorders, dementia
  • History of substance use disorder
  • Inability to provide
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    Erector Spinae Plane (ESP) Block

    Participants will receive an ultrasound-guided thoracic erector spinae plane (ESP) block at the thoracic level corresponding to the location of maximal pain. Under ultrasound guidance, a 22-gauge needle will be advanced into the fascial plane deep to the erector spinae muscle and superficial to the transverse process. Participants will receive 5 mL of 0.5% plain bupivacaine per side, with bilateral injections performed when clinically indicated for bilateral thoracic pain.

    Drug: Erector Spinae Plane (ESP) Block with 0.5% Plain Bupivacaine

  • Active comparator
    Trigger Point Injection (TPI)

    Participants will receive ultrasound-guided trigger point injection(s) into the thoracic paraspinal musculature at the site(s) of maximal tenderness. Under ultrasound guidance, 0.5% plain bupivacaine will be injected in volumes of 1-2 mL per injection site, with a maximum total volume of 5 mL per side and up to five injection sites per laterality.

    Drug: Trigger Point Injection (TPI) with 0.5% Plain Bupivacaine

Interventions

  • DrugErector Spinae Plane (ESP) Block with 0.5% Plain Bupivacaine

    Participants will receive an ultrasound-guided thoracic erector spinae plane (ESP) block at the thoracic level corresponding to the location of maximal pain. Under ultrasound guidance, a 22-gauge needle will be advanced into the fascial plane deep to the erector spinae muscle and superficial to the transverse process. Participants will receive 5 mL of 0.5% plain bupivacaine per side, with bilateral injections performed when clinically indicated for bilateral thoracic pain.

  • DrugTrigger Point Injection (TPI) with 0.5% Plain Bupivacaine

    Participants will receive ultrasound-guided trigger point injection(s) into the thoracic paraspinal musculature at the site(s) of maximal tenderness. Under ultrasound guidance, 0.5% plain bupivacaine will be injected in volumes of 1-2 mL per injection site, with a maximum total volume of 5 mL per side and up to five injection sites per laterality.

06

What researchers measure

Primary outcomes

  1. Numeric Rating Scale (NRS) Pain Score

    A Numeric Rating Scale (NRS) for pain is a patient-reported item regarding the level of pain experienced and is measured on a Likert scale from 0 to 10, where 0 represents "no pain" and 10 represents "the worst pain imaginable".

    Time frame: baseline, 6 weeks

Secondary outcomes

  1. Modified Oswestry Disability Index

    Oswestry Disability Index (ODI) is a validated 10-item questionnaire assessing functional limitations in daily activities across spinal disorders, with total scores ranging from 0 to 100, where higher scores indicate greater disability.

    Time frame: baseline, 6 weeks

  2. Center for Epidemiologic Studies Depression Scale (CES-D)

    Center for Epidemiologic Studies Depression Scale (CES-D) is a 20-item questionnaire with scores ranging from 0 to 60, with higher scores indicating greater depressive symptom burden.

    Time frame: baseline, 6 weeks

  3. Pain Catastrophizing Scale (PCS)

    The PCS is a 13-item instrument measuring catastrophic thinking related to pain, with scores ranging from 0 to 52, and scores of 30 or higher indicating clinically significant levels of catastrophizing.

    Time frame: baseline, 6 weeks

  4. Patient Global Impression of Change (PGIC)

    The PGIC questionnaire is a 7-point Likert scale ranging from "very much worse" to "very much improved." This measure provides a global assessment of treatment benefit from the patient's perspective.

    Time frame: 6 weeks

  5. Repeat Injections

    This measure will assess the number of patients requiring repeat injection(s) within 12 weeks following the index procedure. Measurement: Binary outcome (yes/no), obtained via follow-up assessment of medical record review (no patient questionnaire).

    Time frame: 12 weeks

  6. Adverse Events

    We will assess the occurrence of procedure-related adverse events within 6 weeks following the index procedure. This will involve categorical recording of adverse events including but not limited to: injection site pain, hematoma, infection, vasovagal reaction, allergic reaction, pneumothorax, and new or worsening neurologic symptoms. All adverse events will be recorded and categorized according to severity and relatedness to the procedure.

    Time frame: Day 0 (procedure day), 6 weeks

Other outcomes

  1. Fasciculation (in Trigger Point Injection Cohort Only)

    Proceduralist will document occurrence (yes/no) of muscle fasciculation while performing trigger point injection.

    Time frame: Day 0 (procedure day)

  2. Taut band Visualization (in Trigger Point Injection Cohort Only)

    The proceduralist will document ultrasound visualization of a taut band (yes/no) while performing trigger point injection only.

    Time frame: Day 0 (procedure day)

  3. Numeric Rating Scale (NRS) Pain Score During and After Injection

    A Numeric Rating Scale (NRS) for pain is a patient-reported item regarding the level of pain experienced and is measured on a Likert scale from 0 to 10, where 0 represents "no pain" and 10 represents "the worst pain imaginable". Participants will be asked to rate their worst injection pain experienced during the procedure, and also to rate their immediate post-procedural pain intensity.

    Time frame: Day 0 (procedure day)

07

Study locations

1 of 5 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Aug 2029, 35 months after the start.

Of 15 phase 4 interventional studies under Back Pain, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 40. This study's planned 35 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2026
First posted
Jun 8, 2026
StartActual
Aug 13, 2026
Primary completionEst.
Aug 1, 2029
CompletionEst.
Aug 30, 2029
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07632820
Lead sponsor
Mayo Clinic
Responsible party
Ryan S. D'Souza (Anesthesiologist, Pain Physician, Mayo Clinic) — Principal investigator
First posted
Jun 8, 2026
Start date
Aug 13, 2026
Primary completion
Aug 1, 2029 (estimated)
Completion
Aug 30, 2029 (estimated)
Last update
Sep 9, 2026

Study contacts

Ryan D'Souza, MD
Contact
dsouza.ryan@mayo.edu
507-284-9696
Ryan D'Souza, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion